Publications
Peer-reviewed articles
Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Feb 20;29(6):690-7. Epub 2010 Dec 28.
Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2011 Apr;96(4):567-73. Epub 2010 Dec 20.
Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 Dec 1;116(23):5432-9. doi: 10.1002/cncr.25509. Epub 2010 Jul 27.
Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):192-6.
Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010 Jun 1;116(11):2655-64.
Elstrom R. Serum lactate in febrile neutropenia: What can it tell us? Cancer Biol Ther. 2010 Apr;9(8):590-1.
Panarelli NC, Furman RR, Wang YL, Elstrom R, Cohen JA, Chadburn A. NK/T cell non-Hodgkin lymphoma in a HIV-positive patient. J Hematop. 2010 Mar 4;3(1):35-40.
Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009 Mar 10;27(8):1209-13. Epub 2009 Feb 2.
Elstrom RL, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematol Oncol Clin North Am. 2008 Oct;22(5):1037-49, x-xi. Review.
Elstrom RL, Leonard JP. FDG-PET scans in patients with lymphoma. Curr Hematol Malig Rep. 2008 Oct;3(4):197-203.
Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol. 2008 Jul;45(3 Suppl 2):S11-6. Review.
Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey TJ, Coleman M, Goldsmith SJ, Leonard JP. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leuk Lymphoma. 2008 Apr;49(4):719-26.
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 May 15;112(10):2228-32.
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008 Mar;49(3):447-50.
Roullet M, Sargent R, Pasha T, Cajiao I, Elstrom R, Smith T, Liebhaber S, Zhang P, Bagg A. ZAP70 expression assessed by immunohistochemistry on peripheral blood: a simple prognostic assay for patients with chronic lymphocytic leukemia. Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):471-6.
Cajiao I, Sargent R, Elstrom R, Cooke NE, Bagg A, Liebhaber SA. Igβ(CD79b)mRNA expression in chronic lymphocytic leaukemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. American Journal of Hematology. 82(8):712-20, 2007.
Roullet M, Sargent R, Pasha T, Cajiao I, Elstrom R, Smith T, Liebhaber S, Zhang P, Bagg A. ZAP70 Expression Assessed by Immunohistochemistry on Peripheral Blood: A Simple Prognostic Assay for Patients with Chronic Lymphocytic Leukemia, Applied Immunohistochemistry and Molecular Morphology. 15(4):471-6, 2007.
Alinari L, Castellucci P, Elstrom R, Ambrosini V, Stefoni V, Nanni C, Berkowitz A, Tani M, Farsad M, Franchi R, Fanti S, Zinzani PL. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leukemia and Lymphoma, 47(10): 2096-101, 2006.
Frey NV, Svoboda J, Andreadis C, Tsai DE, Schuster SJ, Elstrom R, Rubin SC, Nasta SD. Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of literature. Leukemia and Lymphoma, 47(9): 1894-901, 2006.
Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A, Luger SM, Porter DL, Nasta S, Tsai D, Loren AW, Siegel DL, Glatstein E, Alavi A, Stadtmauer EA, Schuster SJ. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant: 38(3):211-6, 2006
Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE. Treatment of PTLD with Rituximab or Chemotherapy. American Journal of Transplantation, 6(3): 569-576, 2006.
Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant, 36 (11): 955-961, 2005.
Vogl DT, Glatstein E, Carver JR, Schuster SJ, Stadtmauer EA, Luger S, Nasta SD, Porter DL, Elstrom R, Tsai DE. Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leukemia and Lymphoma, 46(9): 1313-1320, 2005.
Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Elstrom RL, and Thompson CB, AMPK induction of fatty acid b-oxidation is required to reverse the glucose dependence of Akt-transformed cells. Oncogene, 24(26):4165-4173, 2005.
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang HM, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Research 64(11): 3892-3899, 2004.
Elstrom RL, Tsai D, Alavi A, Vergilio J, Downs L, Schuster SJ. Enhanced marrow FDG uptake related to cytokine induced myeloid hyperplasia by Hodgkin's lymphoma can simulate marrow involvement by lymphoma: implications for interpretation of FDG-PET imaging in clinical staging. Clinical Lymphoma, 5: 62-64, 2004.
Rathmell JC, Elstrom RL, Cinalli RM, Thompson CB. Activated Akt promotes increased resting T cell size, CD-28-independent T cell growth, and development of autoimmunity and lymphoma. Eur J Immunol, 33(8): 2223-2232, 2003.
Elstrom RL, Guan L, Pitsilos S, Bagg A, Downs L, Alavi A, and Schuster SJ. Utility of 18FDG-PET scanning in lymphoma by WHO classification. Blood, 101: 3875-3876, 2003.
Frauwirth KA, Riley JL, Parry RV, Rathmell JC, Harris MH, Plas DR, Elstrom RL, June CH, and Thompson CB. CD28 costimulation enhances T lymphocyte glucose metabolism via PI3K/Akt signaling. Immunity, 16: 769-777, 2002.
Villablanca J, Anderson J, Moseley M, Law C-L, Elstrom R, LeBien T. Differentiation of Normal Human Pre-B Cells in Vitro. J. Exp. Med., 172: 325-334, 1990.
LeBien T, Elstrom R, Moseley M, Kersey J, Griesinger F. Analysis of immunoglobulin and T-cell receptor gene rearrangements in human fetal bone marrow B lineage cells. Blood. 76: 1196-1200, 1990.
Non-Peer Reviewed Publications and Book Chapters:
Elstrom RL and Thompson CB; "Cell life and Cell Death." Clinical Oncology 4th edition, ed. Abeloff M, Armitage J, Kastan M, Niederhuber J; in press.
Elstrom R, "Positron emission tomography in Hodgkin's lymphoma." Haematologica, 91(4): 435, 2006.
Elstrom RL. "The Appropriate Use of PET and Gallium Scans in Lymphoma." Clinical Malignant Hematology, ed. Sekeres MA, Kalaycio ME, and Bolwell BJ, 2007.
Elstrom RL and Thompson CB. "Cell life and cell death." Clinical Oncology 3rd edition, ed. Abeloff M, Armitage J, Kastan M, Niederhuber J; 2003.
Elstrom RL and Thompson CB; "Influencing the Apoptotic Mechanism in Cancer Treatment." Progress in Oncology, p.72-90, ed. DeVita V, Hellman S, Rosenberg S, 2001.
